# A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants

> **NCT06329895** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 15 (actual)

## Conditions studied

- Advanced Non-small Cell Lung Cancer
- EGFR Mutation
- HER2 Mutation
- Healthy Volunteers

## Interventions

- **DRUG:** BAY2927088
- **DRUG:** Dabigatran etexilate
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT06329895
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-25
- **Primary completion:** 2024-06-10
- **Final completion:** 2024-06-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06329895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06329895, "A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06329895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*